Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cognition Platform Validation with Donepezil in Early AD
NCT04730635Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) comparing Donepezil with Placebo (2 arms). Primary endpoint: Change From Baseline in Averaged Correct Response Rate on the One Card Learning Task at 8 weeks. Started Mar 2021; status: completed.
02
Drugs
donepezil
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT04730635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04730635.